Focused On-demand Library for Interferon regulatory factor 2-binding protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q7Z5L9

UPID:

I2BP2_HUMAN

Alternative names:

Alternative UPACC:

Q7Z5L9; B1AM35; B1AM36; Q6P083; Q7Z5L8; Q8N351; Q8WUH8

Background:

Interferon regulatory factor 2-binding protein 2 plays a pivotal role in various cellular processes, including acting as a transcriptional corepressor and coactivator in specific contexts. It is involved in repressing the NFAT1-dependent transactivation and in the differentiation of immature B-cells, highlighting its multifaceted role in immune regulation and cellular differentiation.

Therapeutic significance:

Linked to Immunodeficiency, common variable, 14 (CVID14), a condition characterized by recurrent infections and hypogammaglobulinemia, this protein's genetic variants underscore its clinical relevance. Understanding the role of Interferon regulatory factor 2-binding protein 2 could open doors to potential therapeutic strategies for managing immunodeficiencies.